Tower Research Capital (TRC)’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.4K | Buy |
4,707
+3,986
| +553% | +$53.4K | ﹤0.01% | 2597 |
|
|
2025
Q4 | $11.4K | Sell |
721
-1,154
| -62% | -$14.7K | ﹤0.01% | 3608 |
|
|
2025
Q3 | $22.4K | Sell |
1,875
-3,146
| -63% | -$25.1K | ﹤0.01% | 3212 |
|
|
2025
Q2 | $38K | Buy |
5,021
+2,786
| +125% | +$16.8K | ﹤0.01% | 3205 |
|
|
2025
Q1 | $12.3K | Sell |
2,235
-4,967
| -69% | -$30.7K | ﹤0.01% | 3451 |
|
|
2024
Q4 | $41.4K | Buy |
7,202
+2,274
| +46% | +$21.8K | ﹤0.01% | 2673 |
|
|
2024
Q3 | $51.1K | Buy |
4,928
+2,103
| +74% | +$27.5K | ﹤0.01% | 2708 |
|
|
2024
Q2 | $36.6K | Buy |
2,825
+1,308
| +86% | +$17.7K | ﹤0.01% | 3338 |
|
|
2024
Q1 | $26.5K | Sell |
1,517
-4,984
| -77% | -$65.9K | ﹤0.01% | 2755 |
|
|
2023
Q4 | $61.2K | Buy |
6,501
+277
| +4% | +$2.58K | ﹤0.01% | 2997 |
|
|
2023
Q3 | $69.5K | Buy |
6,224
+4,198
| +207% | +$67.6K | ﹤0.01% | 2268 |
|
|
2023
Q2 | $43.4K | Buy |
2,026
+901
| +80% | +$26.6K | ﹤0.01% | 2697 |
|
|
2023
Q1 | $46K | Buy |
1,125
+790
| +236% | +$37.7K | ﹤0.01% | 2563 |
|
|
2022
Q4 | $15K | Sell |
335
-5,810
| -95% | -$265K | ﹤0.01% | 3411 |
|
|
2022
Q3 | $319K | Sell |
6,145
-6,071
| -50% | -$355K | 0.01% | 1497 |
|
|
2022
Q2 | $577K | Buy |
12,216
+1,588
| +15% | +$86.2K | 0.01% | 1045 |
|
|
2022
Q1 | $757K | Buy |
10,628
+7,583
| +249% | +$493K | 0.01% | 911 |
|
|
2021
Q4 | $228K | Buy |
3,045
+1,663
| +120% | +$131K | ﹤0.01% | 1657 |
|
|
2021
Q3 | $79K | Sell |
1,382
-9
| -0.6% | -$445 | ﹤0.01% | 2597 |
|
|
2021
Q2 | $61K | Sell |
1,391
-301
| -18% | -$14.7K | ﹤0.01% | 2857 |
|
|
2021
Q1 | $84K | Buy |
1,692
+772
| +84% | +$38.5K | ﹤0.01% | 2717 |
|
|
2020
Q4 | $39K | Sell |
920
-411
| -31% | -$18.1K | ﹤0.01% | 3343 |
|
|
2020
Q3 | $61K | Sell |
1,331
-1,686
| -56% | -$81.7K | ﹤0.01% | 3450 |
|
|
2020
Q2 | $151K | Buy |
+3,017
| New | +$156K | 0.01% | 2062 |
|
|
2019
Q4 | – | Sell |
-297
| Closed | -$18K | – | 3742 |
|
|
2019
Q3 | $18K | Buy |
+297
| New | +$22.1K | ﹤0.01% | 2532 |
|
|
2019
Q2 | – | Sell |
-161
| Closed | -$15K | – | 3840 |
|
|
2019
Q1 | $15K | Buy |
+161
| New | +$14.4K | ﹤0.01% | 2432 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | – | – | 3929 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | +$100 | ﹤0.01% | 3885 |
|
|
2017
Q2 | – | Sell |
-364
| Closed | -$11K | – | 2890 |
|
|
2017
Q1 | $11K | Sell |
364
-706
| -66% | -$22K | ﹤0.01% | 1684 |
|
|
2016
Q4 | $36K | Buy |
+1,070
| New | +$30.7K | ﹤0.01% | 1651 |
|
|
2016
Q3 | – | Sell |
-300
| Closed | -$7K | – | 3821 |
|
|
2016
Q2 | $7K | Buy |
300
+93
| +45% | +$2.43K | ﹤0.01% | 3127 |
|
|
2016
Q1 | $6K | Buy |
207
+39
| +23% | +$1.09K | ﹤0.01% | 2512 |
|
|
2015
Q4 | $6K | Buy |
+168
| New | +$5.47K | ﹤0.01% | 2753 |
|
|
2015
Q3 | – | Sell |
-1,260
| Closed | -$57K | – | 4188 |
|
|
2015
Q2 | $57K | Sell |
1,260
-2,187
| -63% | -$85.1K | 0.01% | 1258 |
|
|
2015
Q1 | $106K | Buy |
3,447
+3,408
| +8,738% | +$133K | 0.01% | 837 |
|
|
2014
Q4 | $2K | Buy |
+39
| New | +$1.75K | ﹤0.01% | 3325 |
|
|
2014
Q3 | – | Sell |
-391
| Closed | -$17K | – | 4511 |
|
|
2014
Q2 | $17K | Sell |
391
-91
| -19% | -$3.47K | ﹤0.01% | 1931 |
|
|
2014
Q1 | $19K | Sell |
482
-137
| -22% | -$4.98K | ﹤0.01% | 1927 |
|
|
2013
Q4 | $17K | Sell |
619
-1,696
| -73% | -$41.1K | ﹤0.01% | 2492 |
|
|
2013
Q3 | $53K | Sell |
2,315
-4,580
| -66% | -$87.5K | 0.01% | 1859 |
|
|
2013
Q2 | $122K | Buy |
+6,895
| New | +$134K | 0.01% | 422 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Tower Research Capital (TRC)'s ENTA Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Enanta Pharmaceuticals (ENTA) stake by 553% in Q1 2026, buying an estimated $53.4K and bringing the position to 4,707 shares worth $59.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2597.
Tower Research Capital (TRC) first reported a position in ENTA in Q2 2013 and has held it in 40 quarters since. The position peaked at $757K in Q1 2022. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Tower Research Capital (TRC) held 4,707 shares of Enanta Pharmaceuticals worth $59.4K as of Q1 2026.
- Tower Research Capital (TRC) bought 3,986 Enanta Pharmaceuticals shares in Q1 2026, an estimated $53.4K.
- Enanta Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2597 holding.
- Tower Research Capital (TRC) first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- Tower Research Capital (TRC)'s Enanta Pharmaceuticals position peaked at $757K in Q1 2022.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.